Methods. The sample size was 55 BCCs, and the cases were assigned to 2 groups consecutively: 35 BCCs were treated 3 times weekly for 8 weeks, and 20 BCCs were treated 5 times weekly for 5 weeks. Inclusion criteria were age 18 years or older; primary BCC larger than 8 mm; and a superficial, nodular, or infiltrative histologic pattern. 1 Exclusion criteria were pregnancy; immunosuppression; and genetic predisposition to BCC and other histologic subtypes of BCC. Diagnosis was verified on histologic findings in 1 biopsy specimen prior to treatment.
All patients applied 24 doses of imiquimod (Aldara, 3M Pharmaceuticals, St Paul, Minn) to the BCC lesion at night without occlusion. A 4-mm punch biopsy specimen was taken during the first 3 weeks of therapy to study the mechanism of action of imiquimod in BCC, 2 and a final biopsy specimen was obtained 6 weeks after treatment to assess clearance of BCC. Patients whose BCCs had cleared after treatment were visited regularly for 5 years. The main outcome measures of the study were the intent-to-treat long-term clearance rate and the recurrence rate of the imiquimod-treated BCCs. We used the t test, 2 test, Fisher exact test, and multivariate analyses in our statistical analysis (SPSS, version 11.5; SPSS Inc, Chicago, Ill).
Results.
Fifty patients with a total of 4 superficial, 8 nodular, and 43 infiltrative BCCs (n=55) were enrolled in 2001. The clinical and tumor characteristics are summarized in the Table, and subject disposition during the study is shown in Figure 1 .
Forty-two treated BCCs (76%) showed no clinical sign of tumor or histologic tumor signs in the 6-week posttreatment biopsy specimen; all of these patients were observed periodically for a mean of 53 months (range, 10-61 months). During this period, 1 patient died; 4 patients were lost to follow-up with no sign of recurrence at their last visit; and a 76-year-old woman developed a recurrent infiltrative BCC after 10 months of follow-up. Late relapses did not occur, and the 5-year recurrence rate was only 2% (1 of 37). None of the remaining 36 BCCs recurred after a mean of 58 months of follow-up (range, 49-61 months). The cosmetic results were excellent in 33% of cases (n=24), but a permanent hypopigmented macule was observed in 67% of cases (n=12) (Figure 2 ). For the intentto-treat data set, the long-term clearance rate for imiquimod was 65% for all BCCs (n=36), 100% for superficial BCCs (n=4), 75% for nodular BCCs (n=6), 60% for infiltrative BCCs (n=26), and 65% for both dosing regimens (n=23 and n=13). Multivariate analysis demonstrated that only baseline BCC size had a significant association with long-term clearance (P=.02) (odds ratio, 0.99; 95% confidence interval, 0.98-0.10): the smaller the tumor, the higher the chance to be cured with imiquimod.
Comment. To our knowledge, this is the first follow-up study examining topical imiquimod for the treatment of BCCs. Our long-term clearance rates of superficial and nodular BCCs are similar to the short-term rates found in randomized controlled trials, which range from 69% to 100% for superficial BCC 3-8 and 42% to 76% for nodular BCC. 8, 9 Moreover, 60% of infiltrative BCCs in the present study did not recur by the end of the study.
However, the comparison of our results with those of previously reported studies is complicated owing to differences in patient and tumor selection, dosing regimens, number of biopsies performed, and follow-up times. Our results may be biased by the biopsy specimens taken during treatment, which could have removed tumor mass, increased imiquimod absorption, and/or induced a host immunologic reaction resulting in tumor regression.
Nonetheless, our cases were treated with 24 doses of imiquimod on 2 dosing schedules. Imiquimod is approved for 5-times-a-week dosing for 6 weeks (30 doses) for superficial BCC. Surprisingly, only 1 recurrence (2%) was found. Imiquimod treatment provided long-term clinical benefit in 36 (86%) of the 42 BCCs initially cleared.
An ongoing 5-year study is currently being conducted in Europe to monitor possible recurrences of superficial BCC following successful treatment with imiquimod. 10 This study has enrolled patients with a total of 162 BCCs, and the interim 2-year results have shown 14 recurrences (recurrence rate of 8%), but this does not include a histologic assessment after therapy, as we did.
In conclusion, our data suggest that imiquimod treatment is effective in most cases of noninfiltrative BCCs, but more trials are required to determine the therapeutic role of imiquimod for infiltrative BCCs, either alone or in combination with other therapies. 
Scalp Biopsy Specimens: Transverse vs Vertical Sections
E valuation of hair loss continues to be a challenge for dermatologists and pathologists. Current trend favors the examination of both vertical and transverse sections of scalp biopsy specimens, although it is not clear if this is owing to opinion or evidence. Proponents of transverse sections claim that this approach is better because one can (1) examine more follicles at various levels; (2) determine the total number of terminal follicles; and (3) better appreciate infiltrates. In contrast, those who prefer vertical sections indicate that (1) any structure of the follicle examined with transverse sections can be seen with vertical sections; (2) very few follicles are needed to make the correct diagnosis; (3) the total number of terminal follicles is the least important criterion; and (4) infiltrates can be adequately assessed by pattern recognition.
To gather our own experience we performed a prospective study of 276 Mexican patients whose main complaint was hair loss. Institutional review board approval was obtained. There were 107 male and 169 female subjects ranging in age from 10 to 85 years. Each patient had two 4-mm punch biopsy specimens taken: one for vertical and the other for transverse sectioning under hematoxylin-eosin microscopy. The final diagnoses are summarized in the Table. After analysis, our results can be summarized as follows:
1. Both vertical and transverse sections were adequate to assess infiltrates and structure of follicles at various levels and to detect clues for diagnosis; 2. Transverse sections showed more follicles; 3. Vertical sections were adequate for both scarring and nonscarring alopecias; and 4. Both vertical and transverse sections rendered a concordant diagnosis in 100% of cases.
In conclusion, we found both vertical and transverse sections adequate for diagnosis of scarring and nonscarring alopecias. Each technique offered some advantages, but neither was superior to the other. The examination of both transverse and vertical sections is beneficial but not essential, and this minimal benefit must be balanced against added costs and/or inconvenience for patients. 
COMMENTS AND OPINIONS

Rebound Vasodilation From Long-term Topical Corticosteroid Use
T he Cutting Edge article "Successful Treatment of Severe Atopic Dermatitis in a Child and an Adult With the T-Cell Modulator Efalizumab" 1 in the May 2006 issue of the ARCHIVES discusses another medication for this disease with both short-and long-term potential for toxic effects added to the panoply of similar medications, including azathioprine, mycophenolate, cyclosporine, and other immunomodulators. As yet unknown adverse effects of efalizumab might preclude its long-term use. I suggest another approach to the "problem" of atopy before instituting treatments with new medications.
In the case report by Weinberg and Siegfried, 1 a diffuse erythema coupled with the typical eczematous patches in the popliteal area is seen in patient 1. I believe that this diffuse erythema represents corticosteroid addiction with rebound vasodilatation, not worsening eczema. 2-5 Patient 2 demonstrates "spongiotic dermatitis" on the skin biopsy specimen. All of the biopsy specimens from my patients who were addicted to steroids have revealed this same pathologic characteristic. This is not the typical pathologic presentation of atopic dermatitis.
In the past 25 years, I have treated over 1500 patients with these problems (red skin syndrome, red scrotum syndrome, generalized severe atopy, chronic actinic derma- 
